Tilray Brands, Inc. Reports Q3 Fiscal 2024 Financial Results
Achieved Net Revenue of
Beverage-Alcohol Net Revenue Increases 165% Over the Prior
Global Cannabis Net Revenue Increases 33% with International Cannabis Growth of 44% Over the Prior
Conference Call to be Held at
Financial Highlights – 2024 Fiscal Third Quarter
- Net revenue of
$188.3 million increased ~30% in the third quarter compared to$145.6 million in the prior year quarter. - Gross profit was
$49.4 million , while adjusted gross profit increased 17% to$51.6 million in the third quarter. Gross margin was 26% and adjusted gross margin was 27%. - Beverage-alcohol net revenue increased 165% to
$54.7 million in the third quarter from$20.6 million in the prior year quarter. The increase was related to our new Craft Acquisition brands while our existing brands stayed consistent.- Beverage-alcohol gross profit increased 89% to
$18.9 million in the third quarter from$10.0 million in the prior year quarter. Adjusted beverage-alcohol gross profit increased to$20.9 million from$11.0 million in the prior year quarter. - Beverage-alcohol gross margin was 34% in the third quarter compared to 48% in the prior year quarter and adjusted gross beverage alcohol margin was 38% in the third quarter compared to 53% in the prior year quarter. The decrease was a result of the addition of the acquired craft brands, which currently have lower margins than our historical business, primarily due to the current underutilization of the breweries we acquired.
- Beverage-alcohol gross profit increased 89% to
- Cannabis net revenue increased 33% to
$63.4 million in the third quarter compared to$47.5 million in the prior year quarter, reflecting the acquisitions of HEXO and Truss as well as growth in Canadian medical, Canadian adult-use, wholesale, and international.- Cannabis gross profit increased to
$20.9 million in the third quarter from$(32.8) million in the prior year quarter. Adjusted gross profit was$21.1 million compared to$22.2 million in the prior year quarter. - Cannabis gross margin was 33% in the third quarter compared to (69) % in the prior year quarter. Adjusted cannabis gross margin was 33% compared to 47% in the prior year quarter. A portion of the decrease is a result of the termination of the HEXO advisory services agreement which contributed no gross profit in the third quarter compared to
$8.7 million in the prior year quarter, while the remaining decline in gross margin was a result of a change in sales mix.
- Cannabis gross profit increased to
- Distribution net revenue was
$56.8 million in the third quarter compared to$65.4 million in the prior year quarter. Revenue was impacted by short-term challenges related to changes in the regulations pertaining to rebates, IT infrastructure outages and weather.- Distribution (Tilray Pharma) gross margin was 10% in the third quarter compared to 11% in the prior year quarter.
- Wellness net revenue increased 12% to
$13.4 million in the third quarter from$12.0 million in the prior year quarter. The increase was related to our strategic focus on targeted advertising campaigns, coupled with our continuous innovation efforts. - Net loss decreased to
$105.0 million in the third quarter compared to net loss of$1.2 billion in the prior year quarter. Net loss per share narrowed to ($0.12 ) compared to ($1.90 ) in the prior year quarter. - Adjusted EBITDA was
$10.2 million in the third quarter compared to$13.3 million in the prior year quarter. - Strong financial liquidity position of
~$226 million , consisting of$146.3 million in cash and$79.6 million in marketable securities. - Reduced outstanding convertible debt by
$50.7 million compared to the second quarter and a further$41.9 million subsequent to the end of our third quarter. - Net cash used in operating activities improved to
$(15.4) million in the third quarter compared to$(18.6) million in the prior year quarter. The improvement in cash use was primarily related to the achievement of the HEXO and Truss synergies.
Operating Highlights
Strengthened Operations and Financial Position
- Significantly reduced convertible debt by
$205.5 million of principal of outstanding notes through the first three quarter of the fiscal year 2024, including$50.7 million principal reduction during the third quarter 2024, and a further$41.9 million after the period end. We intend to continue to opportunistically repurchase additional notes to optimize our capital structure and enhance financial flexibility. - Achieved
$27.5 million in annualized run-rate savings (and$15.6 million in actual cash cost savings) as part of the$30-$35 million synergy plan related to the HEXO acquisition. - Completed Canadian cannabis business cost reduction plan launched during fiscal year 2022 and international cannabis business plan launched during fiscal year 2023.
Growing Leadership Position in CPG and Beverage-Alcohol
- In
September 2023 ,Tilray expanded and further diversified its beverage portfolio ofSweetWater Brewing Company , Alpine Brewing, Green Flash Brewing, Montauk Brewing, andBreckenridge Distillery by acquiring eight beer and beverage brands from Anheuser-Busch (NYSE: BUD), which elevated us to the 5th largest position in theU.S. craft beer market. The Craft Acquisition brands, which possess strong consumer loyalty and dominate key regions across theU.S. in the Northeast, thePacific Northwest , and the Southeast, areShock Top ,Breckenridge Brewery ,Blue Point Brewing Company , 10Barrel Brewing Company ,Redhook Brewery , Widmer Brothers Brewing,Square Mile Cider Company , and HiBall Energy (the “Craft Acquisition”).Tilray now seeks to become a top 12 U.S. beer and alcohol beverage company through a strategic three-pronged approach that consists of a regional brand growth, national brand expansion, and innovation strategy.- Since the Craft Acquisition,
Tilray has increased the acquired brand category by 2.12% overall, with 10Barrel Brewing Company increasing by 8.5% andRedhook Brewery by 7.0%. According to BI STR data,Tilray has increased its market share of total beer in 13 states, where comparing share before and after the acquisition. We are also the #1 craft supplier in thePacific Northwest , #1 brand family in Metro New York (Montauk Brewing) and the #1 brand family inGeorgia Multi-Outlet (SweetWater Brewing Company ).
- Since the Craft Acquisition,
- Tilray’s wellness brand, Manitoba Harvest, expanded its brand leadership position in the
U.S. andCanada with increased consumption in both the natural and conventional channels as the brand’s top five customers all generating growth. We continue to focus on value-added innovation within the wellness and food beverage space, with the launch of Bio-Active Fiber and protein rich Oatmeal coming to market during the third quarter. In addition, during the latter half of the quarter, we relaunched HiBall energy drinks within the wellness beverages space to complement our Happy Flower CBD beverage launch which occurred in the second quarter.
Leading Global Cannabis Operations, Brands, and Market Share
Tilray continues to lead the Canadian cannabis market in revenue, sales volume, and market share with a 11.6% position during the third quarter. The Company led with #1 share in Cannabis Flower, Oils, Concentrates and THC Beverage product categories.- The HEXO Corp. and Truss Beverage acquisitions together significantly bolstered Tilray’s dominant cannabis position and strengthened low-cost operations and complementary distribution across all Canadian geographies.
Tilray is focused on growing its leading market share in medical cannabis acrossEurope and other international markets. This will be accomplished by capitalizing on its unrivaled cultivation and distribution operations and the leadership team’s depth of commercial and regulatory expertise. During the third quarter, international cannabis net revenue increased by 44% over the prior period driven by growth in our existing markets and expansion into emerging international medical markets.- In the
U.S. today,Tilray does not participate in any cannabis operations and therefore, does not derive any revenue or cash from any cannabis operations in theU.S. The rescheduling of cannabis could open a path forTilray to leverage its expertise in Canadian and European medical cannabis to distribute medical cannabis in theU.S. In the event of federal cannabis legalization in theU.S. , we believe thatTilray is well-positioned to immediately leverage its strongU.S. leadership position and strategic strengths across operations, distribution, and brands to include THC-infused products. We further believe that our MedMen investment in theU.S. will position us to maximize commercial opportunities providing additional revenue opportunities in cannabis.
Updated Fiscal Year 2024 Guidance
For its fiscal year ending
Management’s guidance for Adjusted EBITDA is provided on a non-GAAP basis and excludes transaction expenses, restructuring charges, litigation costs, facility start-up and closure costs, purchase price accounting step-up, changes in fair value of contingent consideration and other items carried at fair value, non-operating income (expenses), and other non-recurring items that may be incurred during the Company's fiscal year 2024, which the Company will continue to identify as it reports its future financial results. Management’s guidance for adjusted free cash flow is provided on a non-GAAP basis and excludes our growth capex, projected integration costs related to HEXO and the Craft Acquisition, and the cash income taxes related to Aphria Diamond.
The Company cannot reconcile its expected adjusted EBITDA to net income or adjusted free cash flow to operating cash flow under “Fiscal Year 2024 Guidance” without unreasonable effort because of certain items that impact net income and other reconciling metrics are out of the Company’s control and/or cannot be reasonably predicted at this time.
Tilray Brands Strategic Growth Actions – 2024 Fiscal Third Quarter
- Tilray Provides International Cannabis Update on Milestone German Cannabis Legalization
- Good Supply Launches New ‘Juiced’ Cannabis Pre-Roll Multi-Packs Across Canada
- Tilray Medical Applauds German Bundestag and Landmark Passage of Medical Cannabis Act in
Germany - Solei Brand Launches New Cannabis Infused Cold
Brew Teas - Two of Oregon’s Favorite Craft Breweries Team Up With the
Portland Timbers as Official Craft Beer Sponsors - SweetWater Brewing Teams Up With Major League Soccer’s Atlanta United FC as Official
Craft Beer Partner - 10
Barrel Brewing Co. Announces Official Beer Sponsorship of the Natural Selection Tour - Widmer Brothers Brewing’s Beloved White Gold Hazy Lager Returns
- 10 Barrel Brewing Launches Pub Ice: a Refreshing Twist on ‘Cheap Fun’
- Blue Point Brewing Announces Its 4th Annual Shakedown on Main Street Festival Featuring Headliners Shaggy,
Bryce Vine , and B.o.B - Breckenridge Distillery Wins World’s Best Finished Bourbon at 2024 World Whiskies Awards
- SweetWater Brewing and Atlanta Track Club Join Forces to Promote Active Lifestyles
Manitoba Harvest Hemp Foods and Brightseed Launch Bio-Active FiberCANADA ! GEARING UP FOR THE BIG GAME?- SweetWater Brewing and Pullman Yards Present 420 Fest on
April 20 & 21, 2024
- Tilray Beers: A Lock for the Big Game
Breckenridge Distillery and Breckenridge Brewery Announce Fourth Edition of Sexy Motor Oil Whiskey and New Sexy Motor Oil Beer- Embrace the Taste of Paradise with Breckenridge Brewery’s Refreshing New ‘Juicy Oasis Fruited Hazy IPA’
- Tilray Brands Completes Acquisition of
Truss Beverage Co. - A Cut Above: RIFF Cannabis Brand Expands Its Diamond Collection With New THCA ‘Liquid Diamond’ Vapes
- Manitoba Harvest Hemp Foods Celebrates a Decade of B Corp Certification With a Score of 100 Points
- SweetWater Brewing Doubles Down on ‘Gummies’
- Tilray Brands Delivers Record Q2 Fiscal 2024 Net Revenue
- Kick off the New Year with a ‘BOOST’ from RIFF Cannabis
- Tilray Launches Cannabis-Infused Premium Belgian Chocolates With Chowie Wowie Edibles Brand
- Alpine Beer’s Fan-Favorite ‘Windows Up’ IPA Returns With Its Signature Tropical Dankness
Breckenridge Distillery Awarded 96 Points and Receives Double Gold and Gold Recognitions at This Year’s 2023New York International Spirits Competition - SweetWater Brewing Announces 27th Anniversary Party Concert Lineup
- Embrace the Chill With Montauk Brewing’s Cold-Weather Beers
- Elevate Everyday Wellness Rituals With Solei Cannabis Teas
- Celebrate This Holiday Season With Delicious and Healthy Baking Recipes
- Tilray Brands Presents the Best Holiday Gifts for Whiskey Enthusiasts and
Craft Beer Lovers - Tilray Brands Unveils Canadian Cannabis Lineup for the Holidays
- Montauk Brewing Expands Distribution Across the Southeast and Launches in
Florida
Live Audio Webcast
About
For more information on how we open a world of wellbeing, visit, Tilray.com and follow @Tilray on all social platforms.
Cautionary Statement Concerning Forward-Looking Statements
Certain statements in this press release constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication.
Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the Company’s ability to become the world's leading cannabis-focused consumer branded company; the Company’s ability to become a leading beverage alcohol Company; the Company’s ability to achieve long term profitability; the Company’s ability to achieve operational scale, market share, distribution, profitability and revenue growth in particular business lines and markets; the Company’s ability to successfully achieve revenue growth, margin and profitability improvements, production and supply chain efficiencies, synergies and cost savings; the Company’s ability to generate
Many factors could cause actual results, performance or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of the Company and the Annual Report on Form 10-K (and other periodic reports filed with the
Use of Non-
This press release and the accompanying tables include non-GAAP financial measures, including Adjusted gross margin, Adjusted gross profit, Adjusted EBITDA, Adjusted net income (loss), Adjusted net income (loss) per share, free cash flow, adjusted free cash flow, constant currency presentations of revenue and cash and marketable securities. Management believes that the non-GAAP financial measures presented provide useful additional information to investors about current trends in the Company's operations and are useful for period-over-period comparisons of operations. These non-GAAP financial measures should not be considered in isolation or as a substitute for the comparable GAAP measures. In addition, these non-GAAP measures may not be the same as similar measures provided by other companies due to potential differences in methods of calculation and items being excluded. They should be read only in connection with the Company's Consolidated Statements of Operations and Cash Flows presented in accordance with GAAP.
Certain forward-looking non-GAAP financial measures included in this press release are not reconciled to the comparable forward-looking GAAP financial measures. The Company is not able to reconcile these forward-looking non-GAAP financial measures to their most directly comparable forward-looking GAAP financial measures without unreasonable efforts because the Company is unable to predict with a reasonable degree of certainty the type and extent of certain items that would be expected to impact GAAP measures but would not impact the non-GAAP measures. Such items may include litigation and related expenses, transaction costs, impairments, foreign exchange movements and other items. The unavailable information could have a significant impact on the Company's GAAP financial results.
The Company believes presenting net sales at constant currency provides useful information to investors because it provides transparency to underlying performance in the Company's consolidated net sales by excluding the effect that foreign currency exchange rate fluctuations have on period-to-period comparability given the volatility in foreign currency exchange markets. To present this information for historical periods, current period net sales for entities reporting in currencies other than the
Adjusted EBITDA is calculated as net income (loss) before income tax benefits, net; interest expense, net; non-operating income (expense), net; amortization; stock-based compensation; change in fair value of contingent consideration; purchase price accounting step-up; impairments; inventory valuation allowance; Other than temporary change in fair value of convertible notes receivable; facility start-up and closure costs; litigation costs; restructuring costs and transaction (income) costs. A reconciliation of Adjusted EBITDA to net loss, the most directly comparable GAAP measure, has been provided in the financial statement tables included below in this press release. Historically, we have included lease expenses for leases that were treated differently under IFRS 16 and ASC 842 in the calculation of adjusted EBITDA, aiming to align our definition with industry peers reporting under IFRS. The decision to include these lease expenses in the Company's definition of adjusted EBITDA was based on our efforts to maintain comparability with peers. However, as the Company has continued to diversify, particularly with strategic acquisitions such as the newly acquired beverage alcohol business portfolio, this comparison is no longer relevant, accordingly, we are no longer including this adjustment. Had the Company continued to include lease expenses that were treated differently under IFRS 16 and ASC 842, the impact to adjusted EBITDA would have been
Contacts:
Media:
news@tilray.com
Investors:
203-682-8253
Raphael.Gross@icrinc.com
Consolidated Statements of Financial Position
(in thousands of US dollars) | 2024 | 2023 | ||||
Assets | ||||||
Current assets | ||||||
Cash and cash equivalents | $ | 146,253 | $ | 206,632 | ||
Marketable securities | 79,605 | 241,897 | ||||
Accounts receivable, net | 89,542 | 86,227 | ||||
Inventory | 244,139 | 200,551 | ||||
Prepaids and other current assets | 43,034 | 37,722 | ||||
Assets held for sale | 28,638 | - | ||||
Total current assets | 631,211 | 773,029 | ||||
Capital assets | 578,783 | 429,667 | ||||
Operating lease, right-of-use assets | 17,453 | 5,941 | ||||
Intangible assets | 930,105 | 973,785 | ||||
2,009,632 | 2,008,843 | |||||
Interest in equity investees | - | 4,576 | ||||
Long-term investments | 8,058 | 7,795 | ||||
Convertible notes receivable | 32,000 | 103,401 | ||||
Other assets | 5,614 | 222 | ||||
Total assets | $ | 4,212,856 | $ | 4,307,259 | ||
Liabilities | ||||||
Current liabilities | ||||||
Bank indebtedness | $ | 15,029 | $ | 23,381 | ||
Accounts payable and accrued liabilities | 209,763 | 190,682 | ||||
Contingent consideration | - | 16,218 | ||||
Warrant liability | 3,182 | 1,817 | ||||
Current portion of lease liabilities | 5,424 | 2,423 | ||||
Current portion of long-term debt | 12,351 | 24,080 | ||||
Current portion of convertible debentures payable | 83,351 | 174,378 | ||||
Total current liabilities | 329,100 | 432,979 | ||||
Long - term liabilities | ||||||
Contingent consideration | 14,000 | 10,889 | ||||
Lease liabilities | 73,228 | 7,936 | ||||
Long-term debt | 165,648 | 136,889 | ||||
Convertible debentures payable | 126,587 | 221,044 | ||||
Deferred tax liabilities | 161,042 | 167,364 | ||||
Other liabilities | 210 | 215 | ||||
Total liabilities | 869,815 | 977,316 | ||||
Stockholders' equity | ||||||
Common stock ( |
77 | 66 | ||||
Preferred shares ( |
- | - | ||||
Additional paid-in capital | 6,030,709 | 5,777,743 | ||||
Accumulated other comprehensive loss | (43,187 | ) | (46,610 | ) | ||
Accumulated Deficit | (2,628,741 | ) | (2,415,507 | ) | ||
3,358,858 | 3,315,692 | |||||
Non-controlling interests | (15,817 | ) | 14,251 | |||
Total stockholders' equity | 3,343,041 | 3,329,943 | ||||
Total liabilities and stockholders' equity | $ | 4,212,856 | $ | 4,307,259 | ||
Condensed Consolidated Statements of Net Income (Loss) and Comprehensive Income (Loss)
For the three months ended | For the nine months ended | |||||||||||||||||||||||||||||||
(in thousands of |
Change | % Change | Change | % Change | ||||||||||||||||||||||||||||
2024 | 2023 | 2024 vs. 2023 | 2024 | 2023 | 2024 vs. 2023 | |||||||||||||||||||||||||||
Net revenue | $ | 188,340 | $ | 145,589 | $ | 42,751 | 29 | % | $ | 559,060 | $ | 442,936 | $ | 116,124 | 26 | % | ||||||||||||||||
Cost of goods sold | 138,944 | 157,288 | (18,344 | ) | (12 | )% | 418,059 | 363,139 | 54,920 | 15 | % | |||||||||||||||||||||
Gross profit (loss) | 49,396 | (11,699 | ) | 61,095 | (522 | )% | 141,001 | 79,797 | 61,204 | 77 | % | |||||||||||||||||||||
Operating expenses: | ||||||||||||||||||||||||||||||||
General and administrative | 39,940 | 38,999 | 941 | 2 | % | 123,769 | 117,385 | 6,384 | 5 | % | ||||||||||||||||||||||
Selling | 9,995 | 6,452 | 3,543 | 55 | % | 24,437 | 25,792 | (1,355 | ) | (5 | )% | |||||||||||||||||||||
Amortization | 21,558 | 23,518 | (1,960 | ) | (8 | )% | 65,700 | 71,872 | (6,172 | ) | (9 | )% | ||||||||||||||||||||
Marketing and promotion | 11,191 | 7,354 | 3,837 | 52 | % | 28,934 | 23,137 | 5,797 | 25 | % | ||||||||||||||||||||||
Research and development | 106 | 171 | (65 | ) | (38 | )% | 241 | 502 | (261 | ) | (52 | )% | ||||||||||||||||||||
Change in fair value of contingent consideration | (5,983 | ) | 352 | (6,335 | ) | (1800 | )% | (16,790 | ) | 563 | (17,353 | ) | (3,082 | )% | ||||||||||||||||||
Impairments | — | 934,000 | (934,000 | ) | (100 | )% | — | 934,000 | (934,000 | ) | (100 | )% | ||||||||||||||||||||
Other than temporary change in fair value of convertible notes receivable | 42,681 | 181,376 | (138,695 | ) | (76 | )% | 42,681 | 181,376 | (138,695 | ) | (76 | )% | ||||||||||||||||||||
Litigation costs, net of recoveries | 3,363 | (5,230 | ) | 8,593 | (164 | )% | 8,439 | (1,970 | ) | 10,409 | (528 | )% | ||||||||||||||||||||
Restructuring costs | 5,178 | 2,663 | 2,515 | 94 | % | 8,748 | 10,727 | (1,979 | ) | (18 | )% | |||||||||||||||||||||
Transaction costs (income) | 3,465 | 5,382 | (1,917 | ) | (36 | )% | 13,061 | (3,882 | ) | 16,943 | (436 | )% | ||||||||||||||||||||
Total operating expenses | 131,494 | 1,195,037 | (1,063,543 | ) | (89 | )% | 299,220 | 1,359,502 | (1,060,282 | ) | (78 | )% | ||||||||||||||||||||
Operating loss | (82,098 | ) | (1,206,736 | ) | 1,124,638 | (93 | )% | (158,219 | ) | (1,279,705 | ) | 1,121,486 | (88 | )% | ||||||||||||||||||
Interest expense, net | (8,517 | ) | (1,040 | ) | (7,477 | ) | 719 | % | (26,977 | ) | (8,560 | ) | (18,417 | ) | 215 | % | ||||||||||||||||
Non-operating income (expense), net | (17,239 | ) | 1,213 | (18,452 | ) | (1,521 | )% | (20,820 | ) | (50,229 | ) | 29,409 | (59 | )% | ||||||||||||||||||
Loss before income taxes | (107,854 | ) | (1,206,563 | ) | 1,098,709 | (91 | )% | (206,016 | ) | (1,338,494 | ) | 1,132,478 | (85 | )% | ||||||||||||||||||
Income tax (recovery) expense | (2,871 | ) | (10,811 | ) | 7,940 | (73 | )% | 1,013 | (15,313 | ) | 16,326 | (107 | )% | |||||||||||||||||||
Net loss | $ | (104,983 | ) | $ | (1,195,752 | ) | $ | 1,090,769 | (91 | )% | (207,029 | ) | (1,323,181 | ) | 1,116,152 | (84 | )% | |||||||||||||||
Net loss per share - basic and diluted | (0.12 | ) | (1.90 | ) | 1.78 | (94 | )% | (0.29 | ) | (2.20 | ) | 1.91 | (87 | )% | ||||||||||||||||||
Condensed Consolidated Statements of Cash Flows
For the nine months ended | ||||||||||||||||
Change | % Change | |||||||||||||||
(in thousands of US dollars) | 2024 | 2023 | 2024 vs. 2023 | |||||||||||||
Cash used in operating activities: | ||||||||||||||||
Net loss | $ | (207,029 | ) | $ | (1,323,181 | ) | $ | 1,116,152 | (84 | )% | ||||||
Adjustments for: | ||||||||||||||||
Deferred income tax recovery | (7,399 | ) | (29,537 | ) | 22,138 | (75 | )% | |||||||||
Unrealized foreign exchange (gain) loss | (6,622 | ) | 13,711 | (20,333 | ) | (148 | )% | |||||||||
Amortization | 95,183 | 101,156 | (5,973 | ) | (6 | )% | ||||||||||
Accretion of convertible debt discount | 11,463 | 7,941 | 3,522 | 44 | % | |||||||||||
Inventory valuation write down | — | 55,000 | (55,000 | ) | (100 | )% | ||||||||||
Impairments | — | 934,000 | (934,000 | ) | (100 | )% | ||||||||||
Other than temporary change in fair value of convertible notes receivable | 42,681 | 181,376 | (138,695 | ) | (76 | )% | ||||||||||
Other non-cash items | 13,297 | 4,990 | 8,307 | 166 | % | |||||||||||
Stock-based compensation | 24,517 | 29,766 | (5,249 | ) | (18 | )% | ||||||||||
(Gain) loss on long-term investments & equity investments | 4,255 | 2,843 | 1,412 | 50 | % | |||||||||||
Loss on derivative instruments | 13,717 | 13,534 | 183 | 1 | % | |||||||||||
Change in fair value of contingent consideration | (16,790 | ) | 563 | (17,353 | ) | (3,082 | )% | |||||||||
Change in non-cash working capital: | ||||||||||||||||
Accounts receivable | 5,578 | 18,053 | (12,475 | ) | (69 | )% | ||||||||||
Prepaids and other current assets | 1,148 | (32,680 | ) | 33,828 | (104 | )% | ||||||||||
Inventory | (4,629 | ) | (11,808 | ) | 7,179 | (61 | )% | |||||||||
Accounts payable and accrued liabilities | (30,982 | ) | (1,419 | ) | (29,563 | ) | 2,083 | % | ||||||||
Net cash used in operating activities | (61,612 | ) | (35,692 | ) | (25,920 | ) | 73 | % | ||||||||
Cash provided by (used in) investing activities: | ||||||||||||||||
Investment in capital and intangible assets, net | (19,539 | ) | (8,394 | ) | (11,145 | ) | 133 | % | ||||||||
Proceeds from disposal of capital and intangible assets | 1,166 | 2,175 | (1,009 | ) | (46 | )% | ||||||||||
Disposal (purchase) of marketable securities, net | 162,292 | (243,186 | ) | 405,478 | (167 | )% | ||||||||||
Business acquisitions, net of cash acquired | (60,626 | ) | (28,122 | ) | (32,504 | ) | 116 | % | ||||||||
Net cash provided by (used in) investing activities | 83,293 | (277,527 | ) | 360,820 | (130 | )% | ||||||||||
Cash provided by (used in) financing activities: | ||||||||||||||||
Share capital issued, net of cash issuance costs | — | 129,593 | (129,593 | ) | (100 | )% | ||||||||||
Shares effectively repurchased for employee withholding tax | — | (1,189 | ) | 1,189 | (100 | )% | ||||||||||
Proceeds from long-term debt | 32,621 | 1,288 | 31,333 | 2,433 | % | |||||||||||
Repayment of long-term debt | (17,978 | ) | (64,658 | ) | 46,680 | (72 | )% | |||||||||
Proceeds from convertible debt | 21,553 | — | 21,553 | NM | ||||||||||||
Repayment of convertible debt | (107,330 | ) | — | (107,330 | ) | NM | ||||||||||
Repayment of lease liabilities | (2,771 | ) | (1,114 | ) | (1,657 | ) | 149 | % | ||||||||
Net increase (decrease) in bank indebtedness | (8,352 | ) | 2 | (8,354 | ) | NM | ||||||||||
Net cash provided by (used in) financing activities | (82,257 | ) | 63,922 | (146,179 | ) | (229 | )% | |||||||||
Effect of foreign exchange on cash and cash equivalents | 197 | (1,615 | ) | 1,812 | (112 | )% | ||||||||||
Net decrease in cash and cash equivalents | (60,379 | ) | (250,912 | ) | 190,533 | (76 | )% | |||||||||
Cash and cash equivalents, beginning of period | 206,632 | 415,909 | (209,277 | ) | (50 | )% | ||||||||||
Cash and cash equivalents, end of period | $ | 146,253 | $ | 164,997 | $ | (18,744 | ) | (11 | )% | |||||||
Net Revenue by Operating Segment
For the three months ended | For the three months ended | For the nine months ended | For the nine months ended | |||||||||||||||||||||||||||||
(In thousands of |
% of Total Revenue | % of Total Revenue | % of Total Revenue | % of Total Revenue | ||||||||||||||||||||||||||||
Beverage alcohol business | $ | 54,688 | 29 | % | $ | 20,640 | 14 | % | $ | 125,355 | 22 |
% | $ | 62,689 | 14 | % | ||||||||||||||||
Cannabis business | 63,432 | 34 | % | 47,549 | 33 | % | 200,879 | 36 | % | 156,017 | 35 | % | ||||||||||||||||||||
Distribution business | 56,794 | 30 | % | 65,385 | 45 | % | 193,174 | 35 | % | 186,158 | 42 | % | ||||||||||||||||||||
Wellness business | 13,426 | 7 | % | 12,015 | 8 | % | 39,652 | 7 | % | 38,072 | 9 | % | ||||||||||||||||||||
Total net revenue | $ | 188,340 | 100 | % | $ | 145,589 | 100 | % | $ | 559,060 | 100 | % | $ | 442,936 | 100 | % | ||||||||||||||||
Net Revenue by Operating Segment in Constant Currency
For the three months ended | For the three months ended | For the nine months ended | For the nine months ended | |||||||||||||||||||||||||||||
(In thousands of |
as reported in constant currency | % of Total Revenue | as reported in constant currency | % of Total Revenue | as reported in constant currency | % of Total Revenue | as reported in constant currency | % of Total Revenue | ||||||||||||||||||||||||
Beverage alcohol business | $ | 54,688 | 29 | % | $ | 20,640 | 14 | % | $ | 125,355 | 23 | % | $ | 62,689 | 14 | % | ||||||||||||||||
Cannabis business | 63,436 | 33 | % | 47,549 | 33 | % | 202,186 | 36 | % | 156,017 | 35 | % | ||||||||||||||||||||
Distribution business | 59,008 | 31 | % | 65,385 | 45 | % | 190,462 | 34 | % | 186,158 | 42 | % | ||||||||||||||||||||
Wellness business | 13,381 | 7 | % | 12,015 | 8 | % | 39,844 | 7 | % | 38,072 | 9 | % | ||||||||||||||||||||
Total net revenue | $ | 190,513 | 100 | % | $ | 145,589 | 100 | % | $ | 557,847 | 100 | % | $ | 442,936 | 100 | % | ||||||||||||||||
Net Cannabis Revenue by Market Channel
For the three months ended | For the three months ended | For the nine months ended | For the nine months ended | |||||||||||||||||||||||||||||
(In thousands of |
% of Total Revenue | % of Total Revenue | % of Total Revenue | % of Total Revenue | ||||||||||||||||||||||||||||
Revenue from Canadian medical cannabis | $ | 6,363 | 10 | % | $ | 6,035 | 13 | % | $ | 18,793 | 10 | % | $ | 18,920 | 12 | % | ||||||||||||||||
Revenue from Canadian adult-use cannabis | 62,107 | 98 | % | 45,318 | 96 | % | 205,350 | 102 | % | 156,063 | 100 | % | ||||||||||||||||||||
Revenue from wholesale cannabis | 2,764 | 4 | % | 58 | 0 | % | 12,348 | 6 | % | 686 | 0 | % | ||||||||||||||||||||
Revenue from international cannabis | 14,002 | 22 | % | 9,707 | 20 | % | 40,185 | 20 | % | 27,834 | 18 | % | ||||||||||||||||||||
Less excise taxes | (21,804 | ) | (34 | )% | (13,569 | ) | (29 | )% | (75,797 | ) | (38 | )% | (47,486 | ) | (30 | )% | ||||||||||||||||
Total | $ | 63,432 | 100 | % | $ | 47,549 | 100 | % | $ | 200,879 | 100 | % | $ | 156,017 | 100 | % | ||||||||||||||||
Net Cannabis Revenue by Market Channel in Constant Currency
For the three months ended | For the three months ended | For the nine months ended | For the nine months ended | |||||||||||||||||||||||||||||
(In thousands of |
as reported in constant currency | % of Total Revenue | as reported in constant currency | % of Total Revenue | as reported in constant currency | % of Total Revenue | as reported in constant currency | % of Total Revenue | ||||||||||||||||||||||||
Revenue from Canadian medical cannabis | $ | 6,307 | 10 | % | $ | 6,035 | 13 | % | $ | 18,994 | 9 | % | $ | 18,920 | 12 | % | ||||||||||||||||
Revenue from Canadian adult-use cannabis | 61,576 | 97 | % | 45,318 | 96 | % | 207,708 | 103 | % | 156,063 | 100 | % | ||||||||||||||||||||
Revenue from wholesale cannabis | 2,763 | 4 | % | 58 | 0 | % | 12,559 | 6 | % | 686 | 0 | % | ||||||||||||||||||||
Revenue from international cannabis | 14,390 | 23 | % | 9,707 | 20 | % | 39,609 | 20 | % | 27,834 | 18 | % | ||||||||||||||||||||
Less excise taxes | (21,600 | ) | (34 | )% | (13,569 | ) | (29 | )% | (76,684 | ) | (38 | )% | (47,486 | ) | (30 | )% | ||||||||||||||||
Total | $ | 63,436 | 100 | % | $ | 47,549 | 100 | % | $ | 202,186 | 100 | % | $ | 156,017 | 100 | % | ||||||||||||||||
Other Financial Information: Key Operating Metrics
For the three months ended | For the nine months ended | |||||||||||||||
(in thousands of |
2024 | 2023 | 2024 | 2023 | ||||||||||||
Net beverage alcohol revenue | $ | 54,688 | $ | 20,640 | $ | 125,355 | $ | 62,689 | ||||||||
Net cannabis revenue | 63,432 | 47,549 | 200,879 | 156,017 | ||||||||||||
Distribution revenue | 56,794 | 65,385 | 193,174 | 186,158 | ||||||||||||
Wellness revenue | 13,426 | 12,015 | 39,652 | 38,072 | ||||||||||||
Beverage alcohol costs | 35,836 | 10,663 | 77,615 | 32,932 | ||||||||||||
Cannabis costs | 42,518 | 80,362 | 139,507 | 137,800 | ||||||||||||
Distribution costs | 51,231 | 57,964 | 172,846 | 165,443 | ||||||||||||
Wellness costs | 9,359 | 8,299 | 28,091 | 26,964 | ||||||||||||
Adjusted gross profit (excluding PPA step-up) | 51,643 | 44,310 | 153,055 | 138,020 | ||||||||||||
Beverage alcohol adjusted gross margin (excluding PPA step-up) | 38 | % | 53 | % | 42 | % | 53 | % | ||||||||
Cannabis adjusted gross margin (excluding PPA step-up) | 33 | % | 47 | % | 34 | % | 47 | % | ||||||||
Distribution gross margin | 10 | % | 11 | % | 11 | % | 11 | % | ||||||||
Wellness gross margin | 30 | % | 31 | % | 29 | % | 29 | % | ||||||||
Adjusted EBITDA | $ | 10,154 | $ | 13,315 | $ | 30,974 | $ | 37,154 | ||||||||
Cash and marketable securities as at the period ended: | 225,858 | 408,283 | 225,858 | 408,283 | ||||||||||||
Working capital as at the period ended: | $ | 302,111 | $ | 288,830 | $ | 302,111 | $ | 288,830 | ||||||||
Other Financial Information: Gross Margin and Adjusted Gross Margin
For the three months ended |
||||||||||||||||||||
(In thousands of |
Beverage | Cannabis | Distribution | Wellness | Total | |||||||||||||||
Net revenue | $ | 54,688 | $ | 63,432 | $ | 56,794 | $ | 13,426 | $ | 188,340 | ||||||||||
Cost of goods sold | 35,836 | 42,518 | 51,231 | 9,359 | 138,944 | |||||||||||||||
Gross profit | 18,852 | 20,914 | 5,563 | 4,067 | 49,396 | |||||||||||||||
Gross margin | 34 | % | 33 | % | 10 | % | 30 | % | 26 | % | ||||||||||
Adjustments: | ||||||||||||||||||||
Purchase price accounting step-up | 2,073 | 174 | — | — | 2,247 | |||||||||||||||
Adjusted gross profit | 20,925 | 21,088 | 5,563 | 4,067 | 51,643 | |||||||||||||||
Adjusted gross margin | 38 | % | 33 | % | 10 | % | 30 | % | 27 | % |
For the three months ended |
||||||||||||||||||||
(In thousands of |
Beverage | Cannabis | Distribution | Wellness | Total | |||||||||||||||
Net revenue | $ | 20,640 | $ | 47,549 | $ | 65,385 | $ | 12,015 | $ | 145,589 | ||||||||||
Cost of goods sold | 10,663 | 80,362 | 57,964 | 8,299 | 157,288 | |||||||||||||||
Gross profit | 9,977 | (32,813 | ) | 7,421 | 3,716 | (11,699 | ) | |||||||||||||
Gross margin | 48 | % | (69 | )% | 11 | % | 31 | % | (8 | )% | ||||||||||
Adjustments: | ||||||||||||||||||||
Inventory valuation adjustments | — | 55,000 | — | — | 55,000 | |||||||||||||||
Purchase price accounting step-up | 1,009 | — | — | — | 1,009 | |||||||||||||||
Adjusted gross profit | 10,986 | 22,187 | 7,421 | 3,716 | 44,310 | |||||||||||||||
Adjusted gross margin | 53 | % | 47 | % | 11 | % | 31 | % | 30 | % |
For the nine months ended |
||||||||||||||||||||
(In thousands of |
Beverage | Cannabis | Distribution | Wellness | Total | |||||||||||||||
Net revenue | $ | 125,355 | $ | 200,879 | $ | 193,174 | $ | 39,652 | $ | 559,060 | ||||||||||
Cost of goods sold | 77,615 | 139,507 | 172,846 | 28,091 | 418,059 | |||||||||||||||
Gross profit | 47,740 | 61,372 | 20,328 | 11,561 | 141,001 | |||||||||||||||
Gross margin | 38 | % | 31 | % | 11 | % | 29 | % | 25 | % | ||||||||||
Adjustments: | ||||||||||||||||||||
Purchase price accounting step-up | 4,426 | 7,628 | — | — | 12,054 | |||||||||||||||
Adjusted gross profit | 52,166 | 69,000 | 20,328 | 11,561 | 153,055 | |||||||||||||||
Adjusted gross margin | 42 | % | 34 | % | 11 | % | 29 | % | 27 | % |
For the nine months ended |
||||||||||||||||||||
(In thousands of |
Beverage | Cannabis | Distribution | Wellness | Total | |||||||||||||||
Net revenue | $ | 62,689 | $ | 156,017 | $ | 186,158 | $ | 38,072 | $ | 442,936 | ||||||||||
Cost of goods sold | 32,932 | 137,800 | 165,443 | 26,964 | 363,139 | |||||||||||||||
Gross profit | 29,757 | 18,217 | 20,715 | 11,108 | 79,797 | |||||||||||||||
Gross margin | 47 | % | 12 | % | 11 | % | 29 | % | 18 | % | ||||||||||
Adjustments: | ||||||||||||||||||||
Inventory valuation adjustments | — | 55,000 | — | — | 55,000 | |||||||||||||||
Purchase price accounting step-up | 3,223 | — | — | — | 3,223 | |||||||||||||||
Adjusted gross profit | 32,980 | 73,217 | 20,715 | 11,108 | 138,020 | |||||||||||||||
Adjusted gross margin | 53 | % | 47 | % | 11 | % | 29 | % | 31 | % | ||||||||||
Other Financial Information: Adjusted Earnings Before Interest, Taxes and Amortization
For the three months ended | For the nine months ended | |||||||||||||||||||||||||||||||
Change | % Change | Change | % Change | |||||||||||||||||||||||||||||
(In thousands of |
2024 | 2023 | 2024 vs. 2023 | 2024 | 2023 | 2024 vs. 2023 | ||||||||||||||||||||||||||
Net loss | $ | (104,983 | ) | $ | (1,195,752 | ) | $ | 1,090,769 | (91 | )% | $ | (207,029 | ) | $ | (1,323,181 | ) | $ | 1,116,152 | (84 | )% | ||||||||||||
Income tax expense | (2,871 | ) | (10,811 | ) | 7,940 | (73 | )% | 1,013 | (15,313 | ) | 16,326 | (107 | )% | |||||||||||||||||||
Interest expense, net | 8,517 | 1,040 | 7,477 | 719 | % | 26,977 | 8,560 | 18,417 | 215 | % | ||||||||||||||||||||||
Non-operating income (expense), net | 17,239 | (1,213 | ) | 18,452 | (1,521 | )% | 20,820 | 50,229 | (29,409 | ) | (59 | )% | ||||||||||||||||||||
Amortization | 32,842 | 33,769 | (927 | ) | (3 | )% | 95,183 | 101,156 | (5,973 | ) | (6 | )% | ||||||||||||||||||||
Stock-based compensation | 8,059 | 9,630 | (1,571 | ) | (16 | )% | 24,517 | 29,766 | (5,249 | ) | (18 | )% | ||||||||||||||||||||
Change in fair value of contingent consideration | (5,983 | ) | 352 | (6,335 | ) | (1,800 | )% | (16,790 | ) | 563 | (17,353 | ) | (3,082 | )% | ||||||||||||||||||
Impairments | - | 934,000 | (934,000 | ) | (100 | )% | - | 934,000 | (934,000 | ) | (100 | )% | ||||||||||||||||||||
Other than temporary change in fair value of convertible notes receivable | 42,681 | 181,376 | (138,695 | ) | (76 | )% | 42,681 | 181,376 | (138,695 | ) | (76 | )% | ||||||||||||||||||||
Inventory valuation adjustments | - | 55,000 | (55,000 | ) | (100 | )% | - | 55,000 | (55,000 | ) | (100 | )% | ||||||||||||||||||||
Purchase price accounting step-up | 2,247 | 1,009 | 1,238 | 123 | % | 12,054 | 3,223 | 8,831 | 274 | % | ||||||||||||||||||||||
Facility start-up and closure costs | 400 | 2,100 | (1,700 | ) | (81 | )% | 1,300 | 6,900 | (5,600 | ) | (81 | )% | ||||||||||||||||||||
Litigation costs, net of recoveries | 3,363 | (5,230 | ) | 8,593 | (164 | )% | 8,439 | (1,970 | ) | 10,409 | (528 | )% | ||||||||||||||||||||
Restructuring costs | 5,178 | 2,663 | 2,515 | 94 | % | 8,748 | 10,727 | (1,979 | ) | (18 | )% | |||||||||||||||||||||
Transaction costs (income) | 3,465 | 5,382 | (1,917 | ) | (36 | )% | 13,061 | (3,882 | ) | 16,943 | (436 | )% | ||||||||||||||||||||
Adjusted EBITDA | $ | 10,154 | $ | 13,315 | $ | (3,161 | ) | (24 | )% | $ | 30,974 | $ | 37,154 | $ | (6,180 | ) | (17 | )% | ||||||||||||||
Other Financial Information: Adjusted net income (loss) per share
For the three months ended | For the nine months ended | |||||||||||||||||||||||||||||||
Change | % Change | Change | % Change | |||||||||||||||||||||||||||||
2024 | 2023 | 2024 vs. 2023 | 2024 | 2023 | 2024 vs. 2023 | |||||||||||||||||||||||||||
Net loss attributable to stockholders of |
$ | (92,701 | ) | $ | (1,170,998 | ) | $ | 1,078,297 | (92 | )% | $ | (213,234 | ) | $ | (1,313,943 | ) | $ | 1,100,709 | (84 | )% | ||||||||||||
Non-operating income (expense), net | 17,239 | (1,213 | ) | 18,452 | (1,521 | )% | 20,820 | 50,229 | (29,409 | ) | (59 | )% | ||||||||||||||||||||
Amortization | 32,842 | 33,769 | (927 | ) | (3 | )% | 95,183 | 101,156 | (5,973 | ) | (6 | )% | ||||||||||||||||||||
Stock-based compensation | 8,059 | 9,630 | (1,571 | ) | (16 | )% | 24,517 | 29,766 | (5,249 | ) | (18 | )% | ||||||||||||||||||||
Change in fair value of contingent consideration | (5,983 | ) | 352 | (6,335 | ) | (1,800 | )% | (16,790 | ) | 563 | (17,353 | ) | (3,082 | )% | ||||||||||||||||||
Impairments | — | 934,000 | (934,000 | ) | (100 | )% | — | 934,000 | (934,000 | ) | (100 | )% | ||||||||||||||||||||
Other than temporary change in fair value of convertible notes receivable | 29,023 | 143,687 | (114,664 | ) | (80 | )% | 29,023 | 143,687 | (114,664 | ) | (80 |
)% | ||||||||||||||||||||
Inventory valuation adjustments | — | 55,000 | (55,000 | ) | (100 | )% | — | 55,000 | (55,000 | ) | (100 | )% | ||||||||||||||||||||
Facility start-up and closure costs | 400 | 2,100 | (1,700 | ) | (81 | )% | 1,300 | 6,900 | (5,600 | ) | (81 | )% | ||||||||||||||||||||
Litigation costs, net of recoveries | 3,363 | (5,230 | ) | 8,593 | (164 | )% | 8,439 | (1,970 | ) | 10,409 | (528 | )% | ||||||||||||||||||||
Restructuring costs | 5,178 | 2,663 | 2,515 | 94 | % | 8,748 | 10,727 | (1,979 | ) | (18 | )% | |||||||||||||||||||||
Transaction costs (income) | 3,465 | 5,382 | (1,917 | ) | (36 | )% | 13,061 | (3,882 | ) | 16,943 | (436 | )% | ||||||||||||||||||||
Adjusted net income (loss) | $ | 885 | $ | 9,142 | $ | (8,257 | ) | (90 | )% | $ | (28,933 | ) | $ | 12,233 | $ | (41,166 | ) | 337 | % | |||||||||||||
Adjusted net income (loss) per share - basic and diluted | $ | 0.00 | $ | 0.01 | $ | (0.01 | ) | (100 | )% | $ | (0.04 | ) | $ | 0.02 | $ | (0.06 | ) | (300 | )% | |||||||||||||
Other Financial Information: Free Cash Flow
For the three months ended | For the nine months ended | |||||||||||||||||||||||||||||||
Change | % Change | Change | % Change | |||||||||||||||||||||||||||||
(In thousands of |
2024 | 2023 | 2024 vs. 2023 | 2024 | 2023 | 2024 vs. 2023 | ||||||||||||||||||||||||||
Net cash used in operating activities | $ | (15,361 | ) | $ | (18,632 | ) | $ | 3,271 | (18 | )% | $ | (61,612 | ) | $ | (35,692 | ) | $ | (25,920 | ) | 73 | % | |||||||||||
Less: investments in capital and intangible assets, net | (8,727 | ) | (842 | ) | (7,885 | ) | 936 | % | (18,373 | ) | (6,219 | ) | (12,154 | ) | 195 | % | ||||||||||||||||
Free cash flow | $ | (24,088 | ) | $ | (19,474 | ) | $ | (4,614 | ) | 24 | % | $ | (79,985 | ) | $ | (41,911 | ) | $ | (38,074 | ) | 91 | % | ||||||||||
Add: growth CAPEX | 8,802 | — | 8,802 | NM | 13,647 | — | 13,647 | NM | ||||||||||||||||||||||||
Add: cash income taxes related to Aphria Diamond | 2,117 | 7,283 | (5,166 | ) | (71 | )% | 16,333 | 12,770 | 3,563 | 28 | % | |||||||||||||||||||||
Add: integration costs related to HEXO | 13,810 | — | 13,810 | NM | 25,955 | — | 25,955 | NM | ||||||||||||||||||||||||
Adjusted free cash flow | $ | 641 | $ | (12,191 | ) | $ | 12,832 | (105 | )% | $ | (24,050 | ) | $ | (29,141 | ) | $ | 5,091 | (17 | )% | |||||||||||||
_________________________
1 Expected rankings based on
Source: Tilray Brands, Inc.